Jeffrey E. Lancet - Concepedia

Author

Jeffrey E. Lancet

Also Known As

J E Lancet, J Lancet, J. E. Lancet, J. Lancet, J.E. Lancet, JEFFREY LANCET, Jeffrey E Lancet, Jeffrey E. Lancet, Jeffrey Lancet, Jianguo Tao

881

Publications

15.1K

Citations

H-Index

Concepts

All Affiliations

Moffitt Cancer Center The University of Texas MD Anderson Cancer Center University of South Florida Dana-Farber Cancer Institute Cleveland Clinic

About

Jeffrey E. Lancet is an author at Moffitt Cancer Center specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	37	75	6.4K
2	Health Sciences	20	31	3.8K
3	Public Health	4	4	229
4	Biostatistics	2	2	97
5	Engineering	1	1	44

Jeffrey E. Lancet

173

Publications

12.4K

Citations

H-Index

Page 1

	Year	Citations
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia Jeffrey E. Lancet, Geoffrey L. Uy, Jörge E. Cortes, Journal of Clinical Oncology Mixed-phenotype Acute LeukemiaPharmacotherapyMetronomic ChemotherapyMyeloid NeoplasiaHematological Malignancy	2018	958
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology Margaret O’Donnell, Martin S. Tallman, Camille N. Abboud, Journal of the National Comprehensive Cancer Network Hematological MalignancyVersion 3.2017OncologyHealth SciencesMixed-phenotype Acute Leukemia	2017	651
Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial Judith E. Karp, Jeffrey E. Lancet, Scott H. Kaufmann, Blood	2001	445
Eprenetapopt (APR-246) and Azacitidine in <i>TP53</i>-Mutant Myelodysplastic Syndromes David A. Sallman, Amy E. DeZern, Guillermo Garcia‐Manero, Journal of Clinical Oncology	2021	436
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology Martin S. Tallman, Eunice S. Wang, Jessica K. Altman, Journal of the National Comprehensive Cancer Network Hematological MalignancyHealth SciencesMedicineAcute Myeloid LeukemiaMixed-phenotype Acute Leukemia	2019	418
Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML Jeffrey E. Lancet, Jörge E. Cortes, Donna E. Hogge, Blood	2014	334
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021 Daniel A. Pollyea, Dale L. Bixby, Alexander E. Perl, Journal of the National Comprehensive Cancer Network Hematological MalignancyTranslational MedicineOncologyMixed-phenotype Acute LeukemiaAcute Myeloid Leukemia	2021	314
Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study Nancy Gillis, Markus Ball, Qing Zhang, The Lancet Oncology Hematological MalignancyOncologyBone Marrow FailureElderly PatientsMalignant Blood Disorder	2016	307
First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia Eric J. Feldman, Jeffrey E. Lancet, Jonathan E. Kolitz, Journal of Clinical Oncology	2011	299
Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes David A. Sallman, Rami S. Komrokji, Christine Vaupel, Leukemia Hematological MalignancyBone Marrow FailureGeneticsAplastic AnemiaHematology	2015	226

Page 1